Cytokines category | Name | Intervention means | Performance | Ending | Refs |
---|---|---|---|---|---|
IL-1 family | IL-1R | IL-1R deficient mice or antagonists | Decrease | Attenuate inflammatory response | |
IL-18 | Treatment with benzyl alcohol and TLR4 knockdown mice | Decrease | Protective role | [180] | |
IL-18 binding protein | Decrease | Protective role | [181] | ||
IL-33 | IL-33 deficient mice | Decrease | Aggravate inflammatory response | ||
Blocking IL-33/IL1RL1 axis | Decrease | Attenuate APAP-mediated organ injury | [74] | ||
IL-36γ | IL-36 receptor antagonist | Decrease | Aggravate liver injury | [184] | |
IL-2 family | IL-4 | IL-4 deficient mice | Decrease | Protective role | [188] |
IL-13 | IL-13 deficient mice | Decrease | Protective role | [187] | |
IL-15 | IL-15 knockout mice | Decrease | Increase susceptibility | [190] | |
IL-6 family | IL-6 | IL-6 deficient mice | Decrease | Increase susceptibility | [193] |
IL-10 family | IL-10 | IL-10 knockdown mice | Decrease | Increase susceptibility | |
SOCS2 knockout mice | Decrease | Enlarge injury site | [200] | ||
IL-22 | In vitro prophylactic injection of IL-22 | Increase | Promote hepatocyte proliferation | [174] | |
IL-22 binding protein | Decrease | Improve inflammatory response | [202] | ||
IL-17 family | IL-17 | IL-17 knockdown mice | Decrease | Attenuate hepatotoxicity | [159] |
Other interleukin cytokines | IL-11 | Deleting IL-11RA1 in hepatocytes/knockdown IL-11 in mice | Decrease | Inhibit hepatocyte death | [215] |
rhIL-11 | In vitro injection | Increase | Protective role | [217] | |
TNF | TNF-α | TNF-α or TNF- R1 deficient mice | Decrease | Attenuate hepatotoxicity | |
TNF-α, TGF-β | NTPDase2 deficient mice | Increase | Aggravate inflammatory response | [232] | |
Interferon | IFN-1 | Interferon α/β receptor deficient mice | Decrease | Delay APAP-mediated liver injury | [236] |
IFN-1R deficient mice | Decrease | Express iNOS impair | [237] | ||
IFN-γ | IFN-γ deficient mice | Decrease | Reduce susceptibility | [111] | |
5-lipoxygenase knockout mice | Decrease | Attenuate liver disease | [233] | ||
MIF knockout mice | Decrease | Attenuate liver disease | [234] | ||
Pretreatment anti-IFN-γ antibody in CCR2 deficient mice | Decrease | Attenuate liver disease | [111] | ||
Growth factor | TGF-β1 | GW788388 | Decrease | Ameliorates hepatocyte inflammation | [245] |
Chemokine family | IL-8 | GRPR antagonists | Decrease | Reduce neutrophil activation | [258] |
CCR2 | CCR2 deficient mice | Decrease | Increase susceptibility | ||
CXCL16 | CXCL16 deficiency mice | Decrease | Reduce neutrophil infiltration | [38] | |
CCL2, CCL3 | Galectin-3 knockout mice | Decrease | Reduce CD11b+/Ly6Chi macrophages | [254] | |
Inflammasome | NALP3 | ASC/ NALP3/caspase1 deficient | Decrease | Disease manifestations were not significantly change | [265] |